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As the title of the special issue indicates,
controversy surrounds augmentation of
brain cognition in humans. Lacking effica-
cious drugs for Alzheimer’s disease (AD)
and with many AD patients recruited for
clinical trials that unfortunately do not
provide the expected results, one wonders
whether to test cognition enhancement
strategies in individuals without symp-
toms of cognition decline. This opin-
ion article presents the view that safe
drugs and or dietary supplements should
be tested worldwide in aged individu-
als under the control of a non-for-profit
organization.
Unfortunately, the effort to translate
the results in rodents into patients with
dementia, mainly of the Alzheimer’s type
has not provided the expected results.
The reasons for the loss-in-translation are
varied (see Franco and Cedazo-Minguez,
2014).Moreover, failures on achieving effi-
cacious anti-AD medications and the high
cost of performing clinical trials make
pharmaceutical companies to abandon
the dementia field (see http://www.abc.
net.au/pm/content/2012/s3611062.htm).
Clinical trials face the difficulty of patient
recruitment and the need—due to ethical
reasons- to maintain the already approved
anti-AD medication. It is difficult to attain
the primary outcomes in AD patients
under a multi-drug treatment regime.
An alternative approach consists of test-
ing cognition enhancement in individuals
not taking anti-AD medication, even in
those without any clinical symptom of
dementia.
A controversy concerning supplements
of vitamin D in individuals with little or
no clinically-relevant symptoms attracted
enough interest to allocate one discussion
session in the 15th European Congress
of Endocrinology held in Copenhagen in
2013. A similar controversy on testos-
terone supplementation exists among
endocrinologists and nutritionists. Solid
reasons emerge for and against the con-
venience of those supplementations; yet
these compounds are easily available. On
analyzing the benefit-risk balance, the
main concern is the side effects that may
appear after chronic treatment with vita-
min D or testosterone. A similar concern
arises on thinking about the possibility
to prescribe cognition enhancers under
a chronically regime. Research in animal
models clearly indicates that cognition
enhancement is possible. Should drugs
with cognition-enhancing potential in
mice models of dementia be tested in
healthy humans? I consider, for instance,
that safe drugs deserve a chance to be
tested in aged non-demented humans.
Relevant for the present discussion is
that drugs may be prescribed to indi-
viduals without any clinical symptom.
Statins, which are inhibitors of 3-hydroxy-
3-methylglutaryl coenzyme A reductase,
are instrumental for the prevention of
cardiovascular dysfunction in hyperc-
holesterolemic patients. Statins are taken
in familial hypercholesterolemia at rela-
tively high doses, chronically and from
very early in life. Statins are safe as deduced
from the records of millions of patients
taken the medication since 1985, when
the first statin was available for human
use. Statin development was on the verge
to be abandoned due to potential side
effects of blood lipid-lowering drugs.
An important pharmaceutical company
took the decision of discontinuing statin
development. Relevant here is that the
“FDA—food and drug administration—
became actively involved in maintaining
interest in the development of the statins.”
Also relevant is that “there was no proof
at that time—early eighties—that drugs
or diet used to lower cholesterol would
be the clinical equivalent of patients with
spontaneously occurring low cholesterol,”
meaning that statins were being devel-
oped without the certainty that lowering
cholesterol by statins could be effica-
cious in combating atherosclerosis. The
full drug development story is avail-
able at http://www.fda.gov/AboutFDA/
WhatWeDo/History/ProductRegulation/Se
lectionsFromFDLIUpdateSeriesonFDAHis
tory/ucm082054.htm. In summary, safe
and efficacious statins are prescribed even
in the absence of clinical symptoms.
Interestingly, some compounds
approved for non-CNS indications have
shown cognition enhancing properties in
animal models of AD. As scientist in a
laboratory on translational AD research I
had experience on two drugs with good
safety records: 4-phenylbutyrate (PBA)
and tadalafil. The first is used in children
with thalassemia, sickle-cell disease or
congenital defects in enzymes of the urea
cycle (Dover et al., 1994; Collins et al.,
1995; Maestri et al., 1996). The second is
one of the phosphodiesterase V inhibitors
prescribed in erectile dysfunction (Boolell
et al., 1996a,b) and pulmonary hyperten-
sion (Prasad et al., 2000; Weimann et al.,
2000; Ghofrani et al., 2004; Kukreja et al.,
2004; Affuso et al., 2006). Two are the
mechanisms underlying the cognition-
enhancing effects of PBA in mouse models
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of AD (reviewed in Cuadrado-Tejedor
et al., 2011a, 2013). On the one hand, PBA
is a chemical chaperone that may help in
preventing the formation of protein aggre-
gates. On the other hand, PBA is a histone
deacetylase inhibitor that enhances the
transcription of genes involved in memory
processes. Inhibition of phosphodiesterase
V is effective in AD models by increas-
ing the concentration of cGMP that in
turn enhances the neural mechanisms
of defense against tau hyperphospho-
rylation and Aß aggregation (Rutten
et al., 2007; Puzzo et al., 2009; Cuadrado-
Tejedor et al., 2011b, 2013; Zhang et al.,
2013; García-Barroso et al., 2013, 2014).
Importantly, whereas acute treatment
did not affect cognitive performance in
healthy individuals (Reneerkens et al.,
2013), a double-blind placebo-controlled
study in patients with erectile dysfunc-
tion showed cognitive enhancement of
a chronically administered phosphodi-
esterase inhibitor (Shim et al., 2014). Even
in a chronic regime phosphodiesterase V
inhibitors are safe (Montorsi et al., 2004;
Giuliano et al., 2010; www.fda.gov/drugs/
drugsafety/ucm390876.htm). To bridge
the gap of successful “anti-AD” therapies
in mice that do not reach humans (see
Franco and Cedazo-Minguez, 2014), safe
drugs could, in my opinion, be the first to
test.
I consider that a non-for-profit organi-
zation such as the US FDA may take the
lead to select 3–4 safe drugs, a couple of
dietary supplements and a placebo, and
design a longitudinal study that should
start in late middle-aged healthy individ-
uals with a lifelong follow-up. Such a
study will take long to give results, but
they would be quite robust and of bet-
ter quality as time passes. In summary my
opinion is that cognitive enhancers in the
form of safe drugs and safe dietary sup-
plements (vitamin C for instance1) should
be tested already in individuals without
clinical symptoms of dementia. Less infor-
mative but easier to implement would
be to follow the age-dependent cognitive
decay in patients taking already chronic
medication for non-CNS indications that
has shown (in mice) cognitive enhancing
1A recent report shows positive results of vitamin C in
both wild type and the APP/PSEN1 animal model of
AD (Kennard and Harrison, 2014).
potential. Such studies would benefit of
the most recent criteria of dementia/AD
diagnosis, of novel behavioral tests and
of novel biomarkers of preclinical phases
of AD (Jack et al., 2011; Sperling et al.,
2011). Likely, the results would indi-
cate the potential of the assayed drugs
for improving cognition and/or delaying
onset of dementia, and the convenience or,
otherwise, the inconvenience of starting
medication in apparently healthy individ-
uals. Even individuals not entering into
dementia might benefit from reducing the
cognitive decline due to aging.
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